...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Dx assays Announces New Companion Diagnostic Partnership Initiative: A Flexible, No Strings Attached, Fee for Service Approach

| Print |
Tuesday, 23 October 2012 09:15 (UTC + 2)

DX-assays_logo

Singapore, October 23, 2012 / B3C newswire / - Dx assays Pte Ltd, the Singapore based provider of contract development services to the global Diagnostics, Pharmaceutical and Biotechnology industries, is pleased to announce that it has launched an unique fee for service companion diagnostic development initiative providing the pharmaceutical companies maximum ownership and control in development, launch and marketing. 

The initiative comes as a response to a growing demand from some pharmaceutical companies for full control over the whole process, from discovery and development to marketing and sales of both the drug and the companion diagnostic. 

“The feedback we have had is that pharmaceutical companies are currently feeling they are facing a risk in traditional companion diagnostic co development deals. Millions of dollars are spent on drug development but, for successful commercialisation, they are fully dependent on an external diagnostic partner for launching and marketing the companion diagnostic. The Dx assays model gives the control back to the pharmaceutical companies. The simple fee for service model offers the pharmaceutical partners exclusive rights to the diagnostics, allowing maximum flexibility on decision making and commercialisation strategy through development for multiple platforms and markets.” says Dr. John Thornback, CEO of Dx assays. 

Dx assays has the capabilities to develop highly generic companion diagnostics, but can also develop specific assays tailored to the needs of a proprietary drug. Since establishment in 2008, Dx assays has carried out over 90 different projects in the field of biomarker assay, companion diagnostic and molecular diagnostic development for different pharmaceutical, diagnostic and biotech customers. Dx assays offers a total package from initial assay development for genetic biomarkers all the way to support in assay validation for clinical trials and assistance in manufacturing and regulatory approval. 

The launch of the initiative exemplifies Dx assays’ philosophy of “Delivering Your Success” focusing on providing top quality innovative projects and products to the Diagnostic, Pharmaceutical and Biotechnology industries. 

Dx assays is exhibiting at the upcoming AMP conference, October 25th-27th in Long Beach, booth 446.

 
About Dx assays
Dx assays is a molecular diagnostic company providing advanced development services within the areas of companion diagnostics and pathogen detection. The company offers flexible partnership models in design, development, verification, clinical validation and manufacturing of molecular diagnostics, companion diagnostics and genetic biomarker assays. 


For further information please contact:
Dx assays
Lisen Sjoberg
Business development executive
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+65 6499 0724